Therapixel garners FDA clearance for mammo AI software

By staff writers

July 9, 2020 -- French artificial intelligence (AI) software developer Therapixel has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MammoScreen software for screening mammography exams.

MammoScreen automatically detects and characterizes suspicious soft-tissue lesions and calcifications on mammography exams, according to the vendor. It then provides a summary report that characterizes the likelihood of malignancy for each lesion with a score from 1 (least likely) to 10 (most likely).

The company said that a multireader, multicase study conducted last year showed that readers using MammoScreen detected more cancers on mammograms than radiologists who did not have access to the software.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking